Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0N71R)

• Drug Name: VY-AADC01 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM0N71R

Molecule-Related Drug Atlas

Drug(s) Targeting Aromatic-L-amino-acid decarboxylase (DDC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vitamin B6	DMDBZMV	Vitamin B6 deficiency	5B5D	Approved	[3]
Carbidopa	DMHRG8Q	Parkinson disease	8A00.0	Approved	[4]
Patrome	DM3H2U4	Parkinson disease	8A00.0	Phase 3	[5]
Benserazide	DMLU8NX	N. A.	N. A.	Phase 3	[4]
AV-201	DMDL9WU	Parkinson disease	8A00.0	Phase 2	[6]
VY-AADC	DMPSBTL	Parkinson disease	8A00.0	Phase 2	[7]
GT-AADC	DM8N3OQ	Aromatic L-amino acid decarboxylase deficiency	5C59.00	Phase 2	[8]
PTC-AADC	DM9ZHE3	Aromatic L-amino acid decarboxylase deficiency	5C59.00	Phase 2	[9]
ProSavin	DMJ42E6	Parkinson disease	8A00.0	Phase 1/2	[10]
OXB-102	DMXF9DM	Parkinson disease	8A00.0	Phase 1/2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aromatic-L-amino-acid decarboxylase (DDC)	TTN451K	DDC_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT03065192) An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to Levodopa. U.S.National Institutes of Health.
• [2] Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial. Neurology. 2022 Jan 4;98(1):e40-e50.
• [3] Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet. 2005 Aug 5;137B(1):1-4.
• [4] Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22.
• [5] The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res. 2000 Nov;6(11):4365-72.
• [6] UCSF report
• [7] Clinical pipeline report, company report or official report of Voyager Therapeutics.
• [8] Clinical pipeline report, company report or official report of PTC Therapeutics.
• [9] ClinicalTrials.gov (NCT04903288) An Open-Label Trial to Address the Safety of the SmartFlow MR-Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Subjects. U.S.National Institutes of Health.
• [10] Clinical pipeline report, company report or official report of Oxford BioMedica.
• [11] Clinical pipeline report, company report or official report of Oxford BioMedica.